Chronic obstructive pulmonary disease in hospital admission in Emilia Romagna region, Part I: The epidemiological burden, year 2003;La broncopneumopatia cronica ostruttiva nei ricoveri ospedalieri della regione Emilia Romagna. Parte I: La dimensione epidemiologica, anno 2003

Rassegna di Patologia dell'Apparato Respiratorio

Volumn 22, Issue 2, 2007, Pages 114-133

  Falcone, Franco ^a   Lucioni, Carlo ^b   Mazzi, Silvio ^b  

^a BELLARIA HOSPITAL   (Italy)

^b Wolters Kluwer Health Italy Ltd   (Italy)

Author keywords

Administrative data; COPD; Diseases related groups; Hospital discharge forms; Hospitalization; International classification of diseases

Indexed keywords

ADULT; AGED; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL INDICATOR; DISEASE CLASSIFICATION; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL ADMISSION; HOSPITAL CARE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; ITALY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MORTALITY; PNEUMONIA; PREVALENCE; QUALITY OF LIFE; REGISTER; RESPIRATORY FAILURE; REVIEW; ROMANIA; SEX DIFFERENCE; STANDARDIZATION;

EID: 36249000565     PISSN: 00339563     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Murray C, Lopez A. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349:1498-504.
2. Jansson S, Andersson F, Borg S, Ericsson A, Jonsson E, Lundback B. Costs of COPD in Sweden according to disease severity. CHEST 2002;122:1994-2002.
3. Hilleman D, Dewan N, Malesker M, Friedman M. Pharmacoeconomic evaluation of COPD. Chest 2000;118:1278-85.
4. Dal Negro R, Rossi A, Cerveri I. The burden of COPD in Italy: results from the Confronting COPD survey. Respir Med 2003;97(Suppl C):S43-S50.
5. Rennard S, Decramer M, Calverley P, Pride N, Soriano J, Vermeire P, et al. Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey. Eur Respir J 2002;20:799-805.
6. Mapel DW, Hurley JS, Frost FJ, Petersen HV, Picchi MA, Coultas DB. Health care utilization in COPD. Arch Int Med 2000;160:2653-8.
7. Strassels SA, Smith DH, Sullivan SD, Mahajan PS. The costs of treating COPD in the United States. Chest 2001;119:344-52.
8. Cote C, Dordelly L, Celli B. Impact of COPD exacerbations on patient-centered outcomes. Chest 2007;131:696-704.
9. Burge S, Wedzicha J. COPD exacerbations: definitions and classifications. Eur Respir J 2003;21 (Suppl 41):46s-53s.
10. Ball P, Harris JM, Lowson D. Acute infective exacerbations of chronic bronchitis. Q J Med 1995;88:61-8.
11. Seemungal TAR, Donaldson GO, Paul EA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-22.
12. National Institutes of Health, National Heart, Lung and Blood Institute. Chronic Obstructive Pulmonary Disease, data fact sheet. Bethesda, MD: NIH Pub. No. 03-5229, 2003.
13. Niederman MS, McCombs JS, Unger AN. Treatment cost of acute exacerbations of chronic bronchitis. Clin Ther 1999;21:576-91.
14. Cydulka RK, McFadden ER Jr, Emerman CL. Patterns of hospitalisation in elderly patients with asthma and chronic obstructive pulmonary diseade. Am J Respir Orit Care Med 1997;156:1807-12.
15. Connors AF Jr, Dawson NV, Thomas C. Outcomes following acute exacerbation of severe chronic obstructive lung disease. Am J Respir Crit Care Med 1996;154:959-67.
16. Andersson F, Borg S, Jansson S-A. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med 2002;96:700-8.
17. Seemungal T, Donaldson G, Bhowmik A, Jeffries D, Wedzicha J. Time course and recovery of exacerbations in patients with COPD. Am J Respir Crit Care Med 2000;161:1608-13.
18. Dewan N, Rafique S, Kanwar B, Satpathy H, Ryschon K, Tillotson G, et al. Acute exacerbations of COPD: factors associated with poor treatment outcome. CHEST 2000;117:662-71.
19. Donaldson G, Seemungal T, Bhowmik A, Wedzicha J. Relationship betwwen exacerbation frequency and lung function decline in COPD. Thorax 2002;57:847-52.
20. Miravitlles M, Murio C, Guerrero T, Gisbert R on behalf of the DAFNE Study Group. Costs of chronic bronchitis and COPD. A 1-year follow-up study. Chest 2003;123:784-91.
21. Lopez-Campos Bodineau L, Fernandez Guerra J, Lara Blanquer A, Perea-Milla Lopez E, Moreno L, Cebrian Gallardo J, et al. Analysis of admissions for chronic obstructive pulmonary disease in Andalusia in 2000. Arch Broncopneumol 2002;38:473-8.
22. Lucioni C, Donner OF, De Benedetto F, Lusuardi M, Mazzi S, Paggiaro PL, et al. I costi della broncopneumopatia cronica ostruttiva in Italia. Presentazione della prima fase dello studio ICE. Pharmacoeconomics Ital Res Articles 2004;6:5-14.
23. Lucioni C, Donner CF, De Benedetto F, Lusuardi M, Mazzi S, Paggiaro PL, et al. I costi della broncopneumopatia cronica ostruttiva: la fase prospettica dello studio ICE (Italian Costs for Exacerbations in COPD). Pharmacoeconomics Ital Res Articles 2005;7:11g-34.
24. Rampulla C, Moretti AM, Sturani C, Arossa W, Falcone F. L'attività di una UO di Pneumologia tipo dalla lettura dei dati del progetto RAPIDO. Rass Patol App Respir 2006;21:121-32.
25. Ballerin L, Potena A, Putinati S, Moretti AM, Sturani C, Arossa W, et al. Progetto RAPIDO: l'insufficienza respiratoria e la patologia ostruttiva. Rass Patol App Respir 2006;21:133-55.
26. Rutten-van Molken MPM, Postman MJ, Joore MA, Van Genugten MLL, Leidl R, Jager JC. Current and future medical costs of asthma and chronic obstructive pulmonary disease in the Netherlands. Respiratory Med 1999;93:779-87.
27. Wilson L, Devine EB, So K. Direct medical costs of chronic obstructive pulmonary disease: chronic bronchitis and emphysema. Respiratory Med 2000;94:204-13.
28. Jacobson L, Hertzman P, Löfdahl Skoogh BE, Lindgren B. The economic impact of asthma and chronic obstructive pulmonary disease (COPD) in Sweden in 1980 and 1991. Respiratory Med 2000;94:247-55.
29. Garcia-Aymerich J, Monsó E, Marrades RM, Escarrabill J, Félez MA, Sunyer J, et the EFRAM investigators. Risk factors for hospitalization for a chronic obstructive pulmonary disease exacerbation. EFRAM STUDY. Am J Respir Crit Care Med 2001;164:1002-7.
30. Kinnunen T, Säynäjäkangas O, Tuuponen T, Keistinen T. Impact of comorbidities on the duration of COPD patients' hospital episodes. Respir Med 2003;97:143-6.
31. Stuart B, Doshi JA, Briesacher B, Wrobel MV, Baysac F. Impact of prescription coverage on hospital and physician costs: a case study of medicare beneficiaries with chronic obstructive pulmonary disease. Clin Ther 2004;10:1688-99.
32. Holguin F, Folch E, Redd S, Mannino D. Comorbidity and mortality in COPD related hospitalizations in the United States, 1979 to 2001. Chest 2005;128:2005-11.
33. Patil S, Krishnan J, Lechtzin N, Diette G. In-Hospital mortality following acute exacerbations of chronic obstructive pulmonary disease. Arch Intern Med 2003;163:1180-6.
34. Kinnunen T, Säynäjäkangas O, Keistinen T. The COPD-induced hospitalization burden from first admission to death. Resp Med 2007;101:294-9.
35. Ng T, Niti M, Tan W. Trends in ethnic differences in COPD hospitalization and mortality in Singapore. COPD 2004;1:5-11.
36. Stanford R, Shen Y, McLaughlin T. Cost of Chronic Obstructive Disease in the emergency department and hospital: an analysis of administrative data from 218 US hospitals. Treat Respir Med 2006;5:343-9.
37. Falcone F, Curcio-Rubertini B, Vizioli M, Ostanello R Analisi delle dimissioni ospedaliere per patologia pneumologica nella regione Emilia Romagna nel triennio 1989-1991. Rass Patol App Respir 1995; 101:119-33.
38. http://www.regione.emilia-romagna.it/sas/nosologiche/.
39. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152:s77-s121.
40. Soriano J, Davis K, Coleman B, Visick G, Mannino D, Pride N. The proportional venn diagram of obstructive lung disease. Two approximations from the United States and the United Kingdom. Chest 2003;124:474-81.
41. Viegi G, Matteelli G, Angino A, Scognamiglio A, Baldacci S, Soriano JB, et al. The proportional Venn diagram of obstructive lung disease in the Italian general population. Chest 2004;126:1093-101.
42. World Health Organization. Manual of the international statistical classification of diseases, injuries and causes of death (vol I). 9th revision. Geneva, Switzerland: World Health Organization 1977.
43. World Health Organization. International statistical classification of diseases and related health problems. 10th revision. Geneva, Switzerland: World Health Organization 1992.
44. Falcone F. Programmare in base all'epidemiologia. Relazione al 38° Congresso Nazionale Associazione Italiana Pneumologi Ospedalieri (AIPO), Sessione Linee Guida ed Evidenze Scientifiche (ottobre 2005, dati non pubblicati).
45. Sullivan SD, Ramsey SD, Lee TA. The Economic Burden of COPD. Chest 2000;117:5S-9S.
46. Antó J, Vermeire P, Vesto J, Sunyer J. Epidemiology of chronic obstructive pulmonary disease. Series "Contributions from the European Respiratory Monographs". Edited by Decramer M, Rossi A. Number 2 in this Series. Eur Respir J 2001;17:982-94.
47. American Thoracic Society/European Respiratory Society Task Force. Standards for the diagnosis and management of patients with COPD [Internet]. Version 1.2. New York: American Thoracic Society 2004.
48. ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Celli BR, MacNee W, and committee members. Eur Respir J 2004;23:932-46.
49. Chapman K, Mannino D, Soriano J, Vermeire P, Buist S, Thune M, et al. Epidemiology and costs of chronic obstructive pulmonary disease. Series "The global burden of chronic obstructive pulmonary disease". Edited by Rabe K, Soriano J. Number 1 in this Series. Eur Respir J 2006;27:188-207.
50. Lopez A, Shibuya K, Rao C, Mathers C, Hansell A, Held L, et al. Chronic obstructive pulmonary disease: current burden and future projections. Series "The global burden of chronic obstructive pulmonary disease". Edited by Rabe K, Soriano J. Number 2 in this Series. Eur Respir J 2006;27:397-412.
51. Pauwels R, Rabe K. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004;364:613-20.
52. Holguin F, Folch E, Redd S, Mannino D. Comorbidity and mortality in COPD related hospitalizations in the United States, 1979 to 2001. Chest 2005; 128:2005-11.
53. Viegi G, Paoletti P, Prediletto R, Carrozzi L, Fazzi P, Di Pede F, et al. Prevalence of respiratory symptoms in an unpolluted area of northern Italy. Eur Respir J 1988;1:311-8.
54. Carrozzi L, Giuliano G, Viegi G, Paoletti P, Di Pede F, Mammini U, et al. The Po River Delta epidemiological study of obstructive lung disease: sampling methods, environmental and population characteristics. Eur J Epidemiol 1990;6:191-200.
55. Viegi G, Scognamiglio A, Baldacci S, Pistelli F, Carrozzi L. Epidemiology of chronic obstructive pulmonary disease (CQPD). Respiration 2001;68:4-19.
56. Viegi G, Matteelli G, Angino A, Scognamiglio A, Baldacci S, Soriano JB, et al. The proportional Venn diagram of obstructive lung disease in the Italian general population. Chest 2004;126:1093-101.
57. ISTAT. Indagine multiscopo sulle famiglie. Roma: Istituto Nazionale di Statistica 1994.
58. Caramori G, Bettoncelli G, Tosatto R, Arpinelli F, Visona G, Invernizzi G, et al. Underuse of spirometry by general practitioners for the diagnosis of COPD in Italy. Monaldi Arch Chest Dis 2005;63:3-5.
59. Kornmann O, Beeha K, Beiera J, Geisa UP, Ksollb M, Buhla R. Newly diagnosed chronic obstructive pulmonary disease. Clinical features and distribution of the novel stages of the global initiative for obstructive lung disease. Respiration 2003;70:67-75.
60. Ekberg-Aronsson M, Pehrsson K, Nilsson JA, Nilsson PM, Löfdahl CG. Mortality in GOLD stages of COPD and its dependence on symptoms of chronic bronchitis. Respiratory Res 2005;6:98.
61. Hoogendorn M, van Molken R, Hoogenveen RT, van Genugten MLL, Buist AS, Wouters EFM, et al. A dynamic population model of disease progression in COPD. Eur Respir J 2005;26:223-33.
62. Stenfors N. Physician-diagnosed COPD global initiative for chronic obstructive lung disease stage IV in Österstund, Sweden. Patient characteristics and estimated prevalence. Chest 2006;130:666-71.
63. Miravitlles M, Murio C, Guerrero T on behalf of the DAFNE Study Group. Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. Eur Respir J 2001;17:928-33.
64. Miravitlles M, Murio C, Guerrero T, Gisbert R for the DAFNE Study Group. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 2002;121:1449-55.
65. Hernandez C. Home hospitalisation of exacerbated chronic obstructive pulmonary disease patients. Eur Respir J 2003;21:58-67.
66. Groenewegen K, Schols A, Wouters E. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest 2003;124:459-67.
67. Roberts C, Barnes S, Lowe D, Pearson M. Evidence for a link between mortality in acute COPD and hospital type and resources. Thorax 2003;58:947-9.
68. Roberts C, Ryland I, Lowe D, Kelly Y, Bucknall C, Pearson M. Audit of acute admissions of COPD: standards of care and management in the hospital setting. Eur Respir J 2001;17:343-9.
69. Gunen H, Hacievliyagil S, Kosar F, Mutlu L, Gulbas G, Pehlivan E, et al. Factors affecting survival of hospitalised patients with CQPD. Eur Respir J 2005;26:234-41.